AG 555, a potent antiretroviral drug, is a potent and selective inhibitor of EGFR and blocks Cdk2 activation^[1][2]. IC50 & Target: EGFR^[1] In Vitro: AG 555 (100 μM) inhibits both the early stages (integration process) and the late stages (viral protein synthesis) in the virus life cycle^[1].
Tyrphostins AG555, which blocks Cdk2 activation, induces growth arrest of immortalized cells at G1-S and early S and is very effective in arresting the growth of EGFR overexpressor cells^[2].
Tyrphostin AG 555 can selectively suppress BPV-1 transcription through MAP kinase pathway activation and binding of phosphorylated Jun/ATF-2 at a novel intragenic regulatory sequence^[3].